ESTRO 2024 - Abstract Book

S1960

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

According to our experience, SBRT on spinal metastases with a median BED of 52.8 Gy results for pain control with an excellent safety and efficacy profile. Pain flare occurred in 11/63 patients, stressing the need for adequate analgesia prior to treatment delivery.

Keywords: pain control, SBRT

References:

[1] Sahgal A, Myrehaug SD, Siva S, Masucci L, Foote MC, Brundage M, Butler J, Chow E, Fehlings MG, Gabos Z, Greenspoon J, Kerba M, Lee YK, Liu MC, Maralani P, Thibault I, Wong R, Hum M, Ding K, Parulekar W. CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1397-1398. doi: 10.1016/j.ijrobp.2020.09.019. Epub 2020 Nov 18. PMID: 33427654. [2] Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 Jun 1;5(6):872-878. doi: 10.1001/jamaoncol.2019.0192. Erratum in: JAMA Oncol. 2021 Oct 1;7(10):1581. PMID: 31021390; PMCID: PMC6487911.

2129

Proffered Paper

Phase 2 Trial of Stereotactic MRI-guided Adaptive Radiation Therapy in One Fraction (SMART ONE)